Nevirapine- Versus Lopinavir/Ritonavir-Based Antiretroviral Therapy in HIV-Infected Infants and Young Children: Long-term Follow-up of the IMPAACT P1060 Randomized Trial
Linda Barlow‐Mosha(MUJHU Research Collaboration), Mark F. Cotton(Stellenbosch University), Enid Kabugho(MUJHU Research Collaboration), Jane C. Lindsey(Harvard University Press), Emily Barr(University at Buffalo, State University of New York), Paul Palumbo(Dartmouth College), Konstantia Angelidou(Harvard University), Avy Violari(University of the Witwatersrand), Portia Kamthunzi, Tapiwa Mbengeranwa(University of Zimbabwe), Patrick Jean-Phillipe(Henry M. Jackson Foundation), Arti Kinikar(B. J. Medical College & Sassoon Hospital), Kunjal Patel(Cancer Research And Biostatistics), Levina Msuya(Christian Medical College, Vellore), Moherndran Archary(Africa Health Research Institute), Lynne Mofenson(Elizabeth Glaser Pediatric AIDS Foundation), Sylvia Dittmer(Perinatal HIV Research Unit), Lee Fairlie(University of the Witwatersrand), Pauline Sambo(University Teaching Hospital)
Cited by 43
Related Papers
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial
|The Lancet|1999|1.7k
Combination Antiretroviral Strategies for the Treatment of Pregnant HIV-1–Infected Women and Prevention of Perinatal HIV-1 Transmission
|JAIDS Journal of Acquired Immune Deficiency Syndromes|2002|896